Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Beam Therapeutics Inc.NASDAQ: BEAM
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $19.28M fell 20.9% year over year, ahead of the -111.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.
Context
- Stock-based compensation amounted to 67.4% of revenue in FY2025, down 122.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -20.9% holds above the trailing-twelve-month pace of -111.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 94.24M USD
- Year-over-year change
- -21.9%
- 4-year CAGR
- +21.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.24M | -21.9% |
| FY2024 | 2024-12-31 | 120.66M | +22.3% |
| FY2023 | 2023-12-31 | 98.65M | +17.0% |
| FY2022 | 2022-12-31 | 84.32M | +93.5% |
| FY2021 | 2021-12-31 | 43.57M | — |
Stock-Based Compensation vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's LTM Jun 2026 stock-based compensation of $12.73M is the 5th largest of the 9 companies compared; the peer median is $16.31M.
- Its year-over-year change of -111.5% is the lowest of 9, against a peer median of -34.0%.
- Stock-based compensation amounts to 8.2% of revenue for BEAM, versus a peer median of 99.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.91M | +2.8% | +19.1% | 220.8% | |
| LTM Sep 2026 | $69.68M | -8.8% | -9.5% | 276.8% | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.47M | -43.3% | -31.8% | 340.0% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| LTM Mar 2026 | $11.16M | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $9.12M | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $8.91M | -28.8% | -19.0% | 19.8% | |
| LTM Mar 2026 | $1.28M | -60.6% | — | 1.9% | |
| Peer median (excluding BEAM) | $16.31M | -34.0% | -19.0% | 99.6% | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (370.64M) | (289.09M) | (132.53M) | (376.74M) | (79.99M) |
| Depreciation & Amortization | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 43.57M | 84.32M | 98.65M | 120.66M | 94.24M |
| Change in Working Capital | 111.25M | 251.63M | (116.46M) | (110.22M) | (131.02M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | 0 | (300M) | 0 | 0 | 0 |
| Accounts Payables | 818K | 2.37M | (7.58M) | 1.81M | 6.04M |
| Other Working Capital | 410.44M | 249.26M | (108.88M) | (112.03M) | (137.06M) |
| Other Non-Cash Items | 142.1M | (38.48M) | (18.87M) | (2.87M) | (250.63M) |
| Operating Cash Flow | (66.27M) | 22.53M | (149.2M) | (347.25M) | (345.1M) |
| Capital Expenditures | (46.81M) | (48.95M) | (33.73M) | (8.95M) | (14.95M) |
| Acquisitions (Net) | 620K | 412.39M | 0 | 0 | (78K) |
| Purchases of Investments | (777.22M) | (1.62B) | (984.34M) | (486.44M) | (1.21B) |
| Sales of Investments | 529.27M | 1.2B | 1.09B | 680.39M | 848.63M |
| Other Investing Activities | 0 | (412.39M) | 0 | 0 | 254.75M |
| Investing Cash Flow | (294.14M) | (461.34M) | 71.84M | 185.01M | (121.44M) |
| Debt Repayment | (2.12M) | (2.29M) | (2.25M) | (485K) | 0 |
| Common Stock Issued | 757.45M | 108.26M | 270.17M | 8.22M | 478.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 810K | 5.62M | 8.53M | 0 | 0 |
| Financing Cash Flow | 756.14M | 111.59M | 276.45M | 7.74M | 478.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 395.73M | (327.22M) | 199.09M | (154.5M) | 11.51M |
| Free Cash Flow | (113.08M) | (26.42M) | (182.93M) | (356.19M) | (360.05M) |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.